Why the study?
Does ibutilide facilitate controlled substrate modification during ablation of persistent atrial fibrillation?
Does ibutilide facilitate controlled substrate modification during ablation of persistent atrial fibrillation?
Answers are grounded in this paper and cite their sources.
Ibutilide may serve as an invaluable adjunct to facilitate controlled substrate modification during ablation of persistent AF, pending results from the ongoing MAGIC-AF trial.
Ablation of peristent AF remains challenging with questions unanswered about what the ideal next step after pulmonary venous isolation should be. Ibutilide is a highly effective class III agent for cardioversion of acute-onset atrial flutter and fibrillation, with limited clinical use due to risks of ventricular pro-arrhythmias. However, results from the on-going MAGIC-AF trial may re-invigorate its role in clinical electrophysiology as an invaluable adjunct to facilitate controlled substrate modification during ablation of persistent AF.
No takes yet. Share an insight, caveat, or question.
Pipin Kojodjojo (2012) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: